Skip to search formSkip to main contentSkip to account menu

PKI 587

Known as: PKI-587, PKI587 
National Institutes of Health

Related topics

Related topics

1 relation
PF-05212384

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Corrigendum to "The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)" [Cancer Lett. 392 (1) (2017) 9-16].
2017
2017
Abstract 325: Pediatric relapsed acute lymphoblastic leukemia patients display enrichment of the PI3K/mTOR pathway and respond to the dual PI3K/mTOR inhibitor PKI-587
2016
2016
Supplementary Material for: Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease
2015
2015
Genomic analysis of PI3K/AKT/mTOR pathway in mesothelioma and treatment of mesothelioma cell lines in vitro using PI3K/mTOR inhibitor PKI-587
Mesothelioma is an aggressive cancer that develops from mesothelial cells, the protective cells that cover many internal organs1… 
2015
2015
First-in-HumanStudyofPF-05212384 ( PKI-587 ) , a Small-Molecule , Intravenous , Dual Inhibitor of PI 3 K and mTOR in Patients with Advanced Cancer
Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity… 
2015
2015
Abstract 670: Targeting PI3K/mTOR leads to MEK/ERK over-activation in pancreatic cancer through suppression of mTORC2
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Significant attention has been given to… 
2014
2014
Abstract 3951: Dual phosphoinositide 3-kinase/Mammalian target of rapamycin inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma
Purpose Although combined chemo-radiotherapy has provided considerable improvements for nasopharyngeal carcinoma (NPC… 
2013
2013
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
2011
2011
Cancer Therapy : Preclinical Antitumor Efficacy of PKI-587 , a Highly Potent Dual PI 3 K / mTOR Kinase Inhibitor
Purpose: The aim of this study was to show preclinical efficacy and clinical development potential of PKI-587, a dual… 
2010
2010
Abstract 723: Beyond temsirolimus: Discovery of PKI-587 a highly efficacious dual PI3K/mTOR inhibitor
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Temsirolimus, a rapamycin analog, is a selective… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)